Type 2 diabetes is an independent risk factor for the development of heart failure. It contributes to adverse cardiac remodeling and it increases heart failure mortality. While cell therapy offers promise for treating heart failure in nondiabetic patients, the efficacy of cell therapy in diabetic hearts remains uncertain. Our preliminary studies show that diabetes impairs cardiac progenitor cell (CPC) growth, survival and differentiation and that CPCs isolated from diabetic hearts fail to promote myocardial recovery after myocardial infarction (MI). We find that CPCs express Glut1 and that their rate of glucose utilization increases in the presence of high extracellular glucose, independently of insulin. Moreover, CPCs isolated from diabetic mice exhibit a marked and sustained increase in aerobic glycolysis, accompanied by an elevated level of 6-phophofructo-2-kinase/fructose-2,6- bisphosphatase 3?a phosphofructokinase 2 isoform known to sustain high rates of glycolysis. Our studies also show that increased glycolytic activity in diabetic CPCs is associated with lower glucose-derived carbon flux through the pentose phosphate and hexosamine biosynthetic pathways, but higher flux through the glycerolipid biosynthetic pathway. These results indicate that high rates of glycolysis in CPCs alter the activity of ancillary pathways of glucose metabolism, which are important for biosynthetic reactions, maintaining redox balance, and for resistance to stress. That such changes in glucose metabolism affect CPC function is indicated by our observation that increasing glycolysis at the PFK step is sufficient to decrease CPC proliferation in vitro. Informed by these observations, we suspect that diabetic dysfunction in CPCs is, at least in part, caused by a dysregulation of glucose metabolism and that correcting this metabolic defect will be a viable approach to optimize cell therapy for the diabetic heart. We propose to test the hypothesis that diabetes leads to an increase in the glycolytic activity in CPCs, which diminishes flux through key ancillary pathways of glucose metabolism. This metabolic dysregulation decreases CPC proliferation, survival, and secretory activity, and impairs the capacity of CPCs to promote myocardial repair. To test this hypothesis, we will: (1) examine how diabetes affects CPC competence and therapy; (2) elucidate the role of glucose metabolism in mediating CPC dysfunction in diabetes; and (3) determine whether rescuing defects in glucose metabolism improves cell therapy in the diabetic heart. Successful completion of the project will provide new understanding of the metabolic pathways that regulate stem/progenitor cell function and how they affect the outcomes of cell therapy for heart failure. These findings would facilitate the optimization of cell therapy protocols and inform ongoing and future cell therapy trials for the treatment of heart failure in both nondiabetic and diabetic patients.

Public Health Relevance

Heart failure is a leading cause of death and is prominent in patients with diabetes. In this project, we will examine the mechanisms by which diabetes impairs cell therapy and how cell therapy can be improved to ameliorate heart failure. These studies could lay the groundwork for the development of novel therapeutic interventions to improve cardiac function in both nondiabetic and diabetic patients with heart failure.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL130174-02
Application #
9277578
Study Section
Myocardial Ischemia and Metabolism Study Section (MIM)
Program Officer
Schwartz, Lisa
Project Start
2016-06-01
Project End
2021-05-31
Budget Start
2017-06-01
Budget End
2018-05-31
Support Year
2
Fiscal Year
2017
Total Cost
$382,834
Indirect Cost
$132,834
Name
University of Louisville
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
057588857
City
Louisville
State
KY
Country
United States
Zip Code
40208
Fulghum, Kyle; Hill, Bradford G (2018) Metabolic Mechanisms of Exercise-Induced Cardiac Remodeling. Front Cardiovasc Med 5:127
Dassanayaka, Sujith; Zheng, Yuting; Gibb, Andrew A et al. (2018) Cardiac-specific overexpression of aldehyde dehydrogenase 2 exacerbates cardiac remodeling in response to pressure overload. Redox Biol 17:440-449
Osuma, Edie A; Riggs, Daniel W; Gibb, Andrew A et al. (2018) High throughput measurement of metabolism in planarians reveals activation of glycolysis during regeneration. Regeneration (Oxf) 5:78-86
Gibb, Andrew A; Hill, Bradford G (2018) Metabolic Coordination of Physiological and Pathological Cardiac Remodeling. Circ Res 123:107-128
Hindi, Sajedah M; Sato, Shuichi; Xiong, Guangyan et al. (2018) TAK1 regulates skeletal muscle mass and mitochondrial function. JCI Insight 3:
Mehra, Parul; Guo, Yiru; Nong, Yibing et al. (2018) Cardiac mesenchymal cells from diabetic mice are ineffective for cell therapy-mediated myocardial repair. Basic Res Cardiol 113:46
Shah, Jasmit S; Rai, Shesh N; DeFilippis, Andrew P et al. (2017) Distribution based nearest neighbor imputation for truncated high dimensional data with applications to pre-clinical and clinical metabolomics studies. BMC Bioinformatics 18:114
DeFilippis, Andrew P; Trainor, Patrick J; Hill, Bradford G et al. (2017) Identification of a plasma metabolomic signature of thrombotic myocardial infarction that is distinct from non-thrombotic myocardial infarction and stable coronary artery disease. PLoS One 12:e0175591
Wei, X; Lorkiewicz, P K; Shi, B et al. (2017) Analysis of Stable Isotope Assisted Metabolomics Data Acquired by High Resolution Mass Spectrometry. Anal Methods 9:2275-2283
Trainor, Patrick J; Hill, Bradford G; Carlisle, Samantha M et al. (2017) Systems characterization of differential plasma metabolome perturbations following thrombotic and non-thrombotic myocardial infarction. J Proteomics 160:38-46

Showing the most recent 10 out of 20 publications